Ionis insider to sell 8,977 shares under Rule 144
Ionis Pharmaceuticals has a planned insider sale disclosed through a Rule 144 notice.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Ionis Pharmaceuticals has a planned insider sale disclosed through a Rule 144 notice. The filing covers the potential sale of 8,977 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an aggregate market value of $684,263.90. These shares were acquired on 01/15/2026 as restricted stock units granted under the company’s 2011 Equity Incentive Plan and classified as compensation. The planned sale date is approximately 01/16/2026. The filing also notes that 161,137,930 shares of Ionis common stock were outstanding, providing context for the size of this transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.